Uniqure Nv Aktie - 0EE0

Professionelle Tools für Privatanleger.

Premium

Current Price

31,50

Gebot

0,00

Fragen

0,00

Volumen

0,00

0,00 Tagesbereich 0,00

31,50 52-Wochen-Bereich 31,50

Marktkapitalisierung

1,532B

Handelsende

31,50

Handelsbeginn

Letzte Trade

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

2.815

Ausgegebene Aktien

48.649.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-2,38

Gewinn pro Aktie (EPS)

-4,92

Erlöse

27,12M

Nettogewinn

-239,56M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.uniqure.com

Hauptsitz

Amsterdam, North Holland, Nld

Gegründet

Uniqure Nv is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0EE0. The last closing price for Uniqure Nv was US$31,50. Over the last year, Uniqure Nv shares have traded in a share price range of US$ 31,50 to US$ 31,50.

Uniqure Nv currently has 48.649.000 shares in issue. The market capitalisation of Uniqure Nv is US$1,53 billion. Uniqure Nv has a price to earnings ratio (PE ratio) of -2.38.

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress ~ Announced alignment with the U.S. Food and Drug Administration...

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its...

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the...

uniQure Announces Pricing of its Public Offering

uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE...

uniQure Announces Proposed Public Offering

uniQure Announces Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a...

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	31.5	31.5	31.5	1534	31.5	DE
4	31.5	31.5	31.5	2437	31.5	DE
12	31.5	31.5	31.5	2815	31.5	DE
26	31.5	31.5	31.5	8486	31.5	DE
52	31.5	31.5	31.5	8952	31.5	DE
156	31.5	31.5	31.5	3379	31.5	DE
260	31.5	31.5	31.5	2135	31.5	DE

0EE0 - Frequently Asked Questions (FAQ)

What is the current Uniqure Nv share price?

The current share price of Uniqure Nv is US$ 31,50

How many Uniqure Nv shares are in issue?

Uniqure Nv has 48.649.000 shares in issue

What is the market cap of Uniqure Nv?

The market capitalisation of Uniqure Nv is USD 1,53B

What is the 1 year trading range for Uniqure Nv share price?

Uniqure Nv has traded in the range of US$ 31,50 to US$ 31,50 during the past year

What is the PE ratio of Uniqure Nv?

The price to earnings ratio of Uniqure Nv is -2,38

What is the cash to sales ratio of Uniqure Nv?

The cash to sales ratio of Uniqure Nv is 20,99

What is the reporting currency for Uniqure Nv?

Uniqure Nv reports financial results in USD

What is the latest annual turnover for Uniqure Nv?

The latest annual turnover of Uniqure Nv is USD 27,12M

What is the latest annual profit for Uniqure Nv?

The latest annual profit of Uniqure Nv is USD -239,56M

What is the registered address of Uniqure Nv?

The registered address for Uniqure Nv is PAASHEUVELWEG 25A, AMSTERDAM, NORTH HOLLAND, 1105 BP

What is the Uniqure Nv website address?

The website address for Uniqure Nv is www.uniqure.com

Which industry sector does Uniqure Nv operate in?

Uniqure Nv operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
CRTCare Reit Plc	108,40p (33,33%)	43,51M
GCMGcm Resources Plc	2,30p (26,03%)	10,32M
DELTDeltic Energy Plc	3,875p (19,23%)	2,79M
ADMEAdm Energy Plc	0,35p (16,67%)	7,67M
CORACora Gold Limited	4,60p (15,58%)	2,27M
SNGSynairgen Plc	1,06p (-46,87%)	3,55M
HEMOHemogenyx Pharmaceuticals Plc	195,00p (-36,17%)	242,53k
HVTHeavitree Brewery Plc	200,00p (-27,27%)	1,6k
ADFFacilities By Adf Plc	20,50p (-26,79%)	1,94M
ROQRoquefort Therapeutics Plc	1,90p (-20,83%)	7,17M
PREMPremier African Minerals Limited	0,0106p (-14,52%)	418,54M
VELAVela Technologies Plc	0,0029p (3,57%)	278,8M
CORCorpus Resources Plc	0,016p (10,34%)	222,68M
SYMESupply@me Capital Plc	0,004p (3,90%)	123,07M
EMEEmpyrean Energy Plc	0,1225p (-3,92%)	93,87M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Uniqure Nv (0EE0)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Uniqure Nv

0EE0 Neueste Nachrichten

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

0EE0 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Uniqure Nv (0EE0) Börsenkurse

Uniqure Nv (0EE0)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Uniqure Nv

0EE0 Neueste Nachrichten

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

0EE0 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen